A nationwide registry-based cohort study of the MammaPrint genomic risk classifier in invasive breast cancer.

CONCLUSIONS: This study showed that MammaPrint classified 52.6% of clinical high risk tumors as genomic low risk. In the Netherlands, 62.7% of the MammaPrint assays from 2013 to 2016 were performed on clinical low risk tumors, although recent International Guidelines recommend its use in clinical high and intermediate risk tumors. PMID: 29310037 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29310037?dopt=Abstract

Source: Breast - January 5, 2018 Category: Cancer & Oncology Authors: Groenendijk FH, Jager A, Cardoso F, van Deurzen CHM Tags: Breast Source Type: research